EUK 134 is a synthetic manganese-porphyrin complex which has been documented to act as a scavenger for oxidative species such as hydrogen peroxide, peroxynitrite and superoxide. This compound is a salen-manganese complex that has been modified to increase its catalase activity while retaining SOD activity.
Chemical Base Information
|Synonyms||EUK 134;SALEN-MN;Salen-Mn-Cl;SALEN-MN/EUK-134;SALEN-MN USP/EP/BP;EUK 134, SOD/catalase mimetic;Manganese (salen-3,3′-diMethoxy) chloride;ETHYLBISIMINOMETHYLGUAIACOL MANGANESE CHLORIDE;chloro(bis(3,3′di-methoxysalicylidene)ethylenediamine)manganese;EUK 134, SOD/catalase mimetic, Ethylbisiminomethylguaiacol manganese chloride|
|melting Point||>300° C|
|Appearance||Dark brown powder|
|Solubility||Soluble in water (0.2 mg/ml at 25° C), PBS pH 7.2, ethanol, DMSO, and DMF.|
|Storage Condition||Store at -20° C|
|Application||EUK-134 has been used as an antioxidant. |
EUK-134 has been used to determine the mechanism underlying hypoxia-inducible factor-1α (HIF-1α) stabilization in human aortic endothelial cells (HAECs).
EUK-134 81065-76-1 General Description
A salen manganese complex with superoxide dismutase (SOD) and catalase mimetic characteristics. EUK134 exhibits potent antioxidant activities, and inhibits the formation of β-amyloid and related amyloid fibril (IAPP). Useful pharmacological tool for the development of new compounds for the treatment of Alzheimer’s and Parkinson’s disease and type 2 diabetes.
In SK-N-MC cells, EUK134 protects neuronal cells against H2O2 toxicity by attenuating oxidative stress through inhibition of MAPK pathway, and also results in decreased expression of pro-apoptotic genes p53 and Bax as well as enhanced expression of anti-apoptotic Bcl-2 gene. Pretreatment with EUK-134 (10 μM) was effective in the prevention of hypertrophic changes in H9C2 cells, reduction of oxidative stress, and prevention of metabolic shift. EUK-134 treatment improved the oxidative status of mitochondria and reversed hypertrophy-induced reduction of mitochondrial membrane potential. Supplementation with EUK-134 is therefore identified as a novel approach to attenuate cardiac hypertrophy and lends scope for the development of EUK-134 as a therapeutic agent in the management of human cardiovascular disease.
EUK-134 81065-76-1 Mechanism Of Action
People consume food and water every day, transport them to various body tissues through the digestive system and circulatory system, and are metabolized in cells to release energy. During the entire metabolism process, a large number of “ROS (reactive oxygen species)” will be produced, including: O2-, H2O2 and HO2-, -OH, etc. These reactive oxygen species can damage the normal cells of the human body, leading to cell apoptosis and even necrosis.
The two important antioxidant components in the human body are: superoxide dismutase (SOD) and catalase (CAT). These two components work closely together to convert the “ROS (Reactive Oxygen Cluster)” produced in the metabolic process into water and oxygen to maintain the body’s normal metabolism.
Due to the high molecular weight of SOD, it is difficult to penetrate the stratum corneum. In addition, even if SOD enters the skin in a small amount through pores and sweat glands, it is easily hydrolyzed by protein and has poor stability and fast metabolism in the human body. These characteristics of SOD prevent its application in cosmetics. Therefore, “EUK-134” was developed to replace the application of SOD and CAT in the cosmetics field.
EUK-134 81065-76-1 Application
Protect against DNA damage
Sunscreen care, supplement the care that general sunscreen ingredients can’t take care of
Fight oxidative stress
EUK-134 81065-76-1 More research
EUK 134 is a salen-manganese complex that has been modified to increase its catalase activity while retaining SOD activity. EUK 134 is a salen-manganese complex that has been modified to increase its catalase activity while retaining SOD activity. EUK 134 consumes hydrogen peroxide with an initial reaction rate of 234 µM/min in vitro.1 EUK 134 is protective in a rat stroke model, employing middle cerebral artery ligation. At 2.5 mg/kg, rats treated with EUK 134 showed reduced infarct volume by more than 80%. EUK 134 at 10 mg/kg also significantly attenuates brain damage in rats following systemic administration of kainic acid.2
EUK-134 81065-76-1 Reference
- J Pharmacol Exp Ther. 1998 Jan;284(1):215-21; Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9897-902; PLoS One. 2017 Feb 2;12(2):e0169146; Mol Cell Biochem. 2016 Sep;420(1-2):185-94.
- J. Ophoven et al. Salen-manganese complexes: sophisticated tools for the analysis of intercellular ROS signaling pathways. Anticancer Res. 2010 Oct;30(10):3967-79.
- Failli et al. A novel manganese complex effective as superoxide anion scavenger and therapeutic agent against cell and tissue oxidative injury. J Med Chem. 2009 Nov 26;52(22):7273-83.
- Decraene et al. A synthetic superoxide dismutase/catalase mimetic (EUK-134) inhibits membrane-damage-induced activation of mitogen-activated protein kinase pathways and reduces p53 accumulation …. J Invest Dermatol. 2004 Feb;122(2):484-91.